Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 1/20 | 0.77 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.77 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.77 |
| ▸ | CTSL | P07711 | 9/20 | 0.72 |
| ▸ | CTSB | P07858 | 6/20 | 0.72 |
| ▸ | CTSK | P43235 | 5/20 | 0.69 |
| ▸ | CTSS | P25774 | 2/20 | 0.65 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mg-132 SCHEMBL7862424 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL160925 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL10006388 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL14579851 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL2522088 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL5062219 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL2535252 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL14514061 | 1.00 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| SCHEMBL7710728 | 0.99 | PSMB1 (0.78) | PSMB1PSMB5PSMB2CTSLCTSB | |
| SCHEMBL3054703 | 0.99 | PSMB1 (0.78) | PSMB1PSMB5PSMB2CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093611-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | AVALON PHARMACEUTICALS, INC. | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093611-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | IKBKB, IKBKG, NFKBIA | PSMB1 14/4885PSMB5 51/4885PSMB2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.